Login to Your Account


Kinder, gentler treatments for older, sicker patients

By Anette Breindl
Science Editor

Monday, December 9, 2013
NEW ORLEANS – Data from much-anticipated studies were revealed at Sunday’s plenary session at the American Society of Hematology’s 55th annual meeting. One was the head-to-head comparison of Genentech Inc./Roche AG’s Gazyva (obinutuzumab/GA101) with Rituxan (rituximab, Biogen Idec.) for the treatment of chronic lymphocytic leukemia (CLL). The other were the results of the FIRST/ MM020 trial comparing Revlimid (lenalidomide, Celgene Corp.) plus dexamethasone to the standard treatment of Melphalan, prednisone and thalidomide (MPT) in stem cell transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. Both drugs spell progress for patients in part because they are less toxic than current regimens.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription